NDC 49643-818

Glycerol-Saline Control

Glycerol-saline Diluent

Glycerol-Saline Control is a Cutaneous; Intradermal; Subcutaneous Injection in the Non-standardized Allergenic category. It is labeled and distributed by Allermed Laboratories, Inc.. The primary component is Glycerin.

Product ID49643-818_4f1be4f6-9f9e-5c19-e054-00144ff8d46c
NDC49643-818
Product TypeNon-standardized Allergenic
Proprietary NameGlycerol-Saline Control
Generic NameGlycerol-saline Diluent
Dosage FormInjection
Route of AdministrationCUTANEOUS; INTRADERMAL; SUBCUTANEOUS
Marketing Start Date1974-03-12
Marketing CategoryBLA / BLA
Application NumberBLA102211
Labeler NameAllermed Laboratories, Inc.
Substance NameGLYCERIN
Active Ingredient Strength1 g/mL
Pharm ClassesNon-Standardized Chemical Allergen [EPC],Increased Histamine Release [PE],Cell-mediated Immunity [PE],Increased IgG Production [PE],Allergens [CS],Glycerol [CS]
NDC Exclude FlagN
Listing Certified Through2019-12-31

Packaging

NDC 49643-818-05

5 mL in 1 VIAL, MULTI-DOSE (49643-818-05)
Marketing Start Date1974-03-12
NDC Exclude FlagN
Sample Package?N

NDC SPL Data Element Entries

NDC 49643-818-10 [49643081810]

Glycerol-Saline Control INJECTION
Marketing CategoryBLA
Application NumberBLA102211
Product TypeNON-STANDARDIZED ALLERGENIC
Marketing Start Date1974-03-12

NDC 49643-818-50 [49643081850]

Glycerol-Saline Control INJECTION
Marketing CategoryBLA
Application NumberBLA102211
Product TypeNON-STANDARDIZED ALLERGENIC
Marketing Start Date1974-03-12

NDC 49643-818-30 [49643081830]

Glycerol-Saline Control INJECTION
Marketing CategoryBLA
Application NumberBLA102211
Product TypeNON-STANDARDIZED ALLERGENIC
Marketing Start Date1974-03-12

NDC 49643-818-05 [49643081805]

Glycerol-Saline Control INJECTION
Marketing CategoryBLA
Application NumberBLA102211
Product TypeNON-STANDARDIZED ALLERGENIC
Marketing Start Date1974-03-12

Drug Details

Active Ingredients

IngredientStrength
GLYCERIN.53 g/mL

Pharmacological Class

  • Non-Standardized Chemical Allergen [EPC]
  • Increased Histamine Release [PE]
  • Cell-mediated Immunity [PE]
  • Increased IgG Production [PE]
  • Allergens [CS]
  • Glycerol [CS]

© 2024 FDA.report
This site is not affiliated with or endorsed by the FDA.